Brunistill Ketotifen Eye Drops 0.5ml 0,025mg
Brunistill Ketotifen Eye Drops 0.5ml 0,025mg 20 Single Dose Brunistill Ketotifen Eye Drops 0.5ml 0,025mg eyewash Composition: A single-dose container 0.5 ml of solution contains: Active ingredient: Ketotifen 125 mcg (as hydrogen fumarate), equivalent to 250 mcg / ml For excipients see 6.1. excipients Glycerol (E422) Sodium hydroxide Purified water.
Therapeutic indications BRUNISTILL is indicated for symptomatic treatment of seasonal allergic conjunctivitis. Contraindications Hypersensitivity to ketotifen or to any of the excipients listed in section 6.1. dosage Adults, elderly and children (over three years): one drop into the conjunctival sac twice a day. The content of a single-dose container is sufficient for one administration in both eyes.
Brunistill Ketotifen Eye Drops 0.5ml 0,025mg Content
Content and container are sterile until the opening of the original closure. To avoid the risk of contamination do not touch any surface with the tip of the container.
Warnings and Precautions No special precautions interactions If you are using other medicines for ocular use, you must leave an interval of at least 5 minutes between one application and another.
Oral administration of ketotifen may potentiate the effects of drugs CNS depressants, antihistamines and alcohol. Although these phenomena were not observed with BRUNISTILL, the possibility of such effects can not be excluded.
Side effects Brunistill Ketotifen Eye Drops 0.5ml 0,025mg
Side effects At the recommended dose have been reported, the following side effects. The frequency listed below is defined using the following convention: very common (≥1 / 10), common (≥1 / 100, <1/10), uncommon (≥1 / 1,000, <1/100) rare (≥1 / 10,000 to <1 / 1,000). By system organ class MedDRA adverse events Frequency Eye disorders: eye irritation, eye pain, punctate keratitis. common blurred vision (during I'instillazione), dry eye, eyelid disorder, conjunctivitis, photophobia, conjunctival haemorrhage. Uncommon Nervous system disorders: headache Uncommon General disorders and administration site conditions drowsiness Uncommon Skin and subcutaneous tissue disorders: rash, eczema, urticaria Uncommon Gastrointestinal disorders: dry mouth Uncommon Immune system disorders: hypersensitivity Uncommon Pregnancy and lactation Non-clinical data on the use of BRUNISTILL pregnancies are available. Animal studies using maternally toxic oral doses showed increased pre- and postnatal mortality, but have not shown teratogenic effects. Systemic levels of ketotifen after ophthalmic application are much lower than those achieved after oral administration. You should still use caution when prescribing to pregnant women. Although data from studies on animals consecutive oral administration show excretion of the active ingredient in breast milk, it is unlikely that topical administration in women can produce detectable amount of active ingredient in breast milk. Mothers who use BRUNISTILL eye drops can then breastfeed.
